封面
市場調查報告書
商品編碼
1327709

多工化驗市場:類型(蛋白質,核酸,細胞)技術(流式細胞技術,PCR,免疫測量)用途(研究開發,診斷產品),各終端用戶-2030年前的世界預測

Multiplex Assays Market by Type (Protein, Nucleic Acid, Cell) Technology (Flow Cytometry, PCR, Immunoassay) Application (R&D, Diagnosis Product), End User - Global Forecast to 2030

出版日期: | 出版商: Meticulous Research | 英文 262 Pages | 訂單完成後即時交付

價格

到 2030 年,全球多工化驗市場預計將達到 62.4 億美元,2023 年至 2030 年複合年增長率為 9.0%。

該報告在廣泛的二級和一級研究以及對市場情景的詳細分析後,對關鍵行業推動因素、限制因素、挑戰和機會進行了分析。該市場的成長是由於多工化驗相對於單一檢測的優勢、多工化驗在伴隨診斷中的應用、慢性病和傳染病患者病率的增加以及人們對早期疾病診斷重要性的認識不斷提高而推動的。這是由於以下幾個原因因素。然而,多工化驗設備的高成本限制了市場的成長。

對高通量、自動化測試系統的需求不斷增長,以及對個人化醫療的日益關注,預計將為該市場的參與者提供成長機會。然而,缺乏熟練的專業人員和交叉反應的風險是市場成長的主要挑戰。

本報告基於對產品組合、區域影響力以及行業領先市場參與者多年來(2020-2023 年)採取的關鍵策略發展的廣泛評估,提供了競爭格局。全球多工化驗市場的主要公司包括 Thermo Fisher Scientific, Inc.(美國)、Bio-Rad Laboratories, Inc.(美國)、Seegene, Inc.(韓國)和 Qiagen NV(荷蘭)。PerkinElmer, Inc.(美國) 、F. Hoffmann-La Roche Ltd.(瑞士)、Agilent Technologies, Inc. Ltd.(瑞士)、Agilent Technologies, Inc.(美國)、Abbott Laboratories(美國)、Siemens Healthineers AG(德國)、Illumina, Inc. (美國)、Becton, Dickinson and Company(美國)、Quanterix Corporation(美國)、DiaSorin SpA(義大利)、Merck KGaA(德國)。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場洞察

    市場
  • 概要
  • 市場成長的影響因素
    • 市場動態
      • 多重測定相對於單一測定的優勢將促使多重測定的採用增加。
      • 多工化驗在伴隨診斷中的使用不斷增加,推動了對多工化驗的需求
      • 多工化驗設備的高成本阻礙了最終用戶的使用
      • 對個人化醫療的興趣日益濃厚,推動了多工化驗的使用
      • 缺乏熟練的專業人員和交叉反應的風險限制了多工化驗的採用
    • 要素分析
  • 技術趨勢
    • 多重 PCR 技術的技術進步
    • 將人工智慧和機器學習整合到多重偵測系統中
    • 開發以智慧型手機為基礎的診斷測試平台
  • 法規分析
    • 北美
      • 美國
      • 加拿大
    • 歐洲
    • 亞太地區
      • 中國
      • 印度
      • 日本
      • 韓國
    • 南美
    • 中東·非洲
  • 價格分析
  • 波特的五力分析

第5章 多工化驗市場評估:各類型

  • 概要
  • 蛋白質多工化驗
    • 以微珠為基礎化驗
    • 平面化驗
  • 核酸多工化驗
  • 細胞為基礎的多工化驗

第6章 多工化驗市場評估:各產品

  • 概要
  • 消耗品
  • 設備
  • 軟體和服務

第7章 多工化驗市場評估:各技術

  • 概要
  • 流式細胞技術
  • 多工免疫測量
  • 多工即時PCR
  • 定序
  • 其他技術

第8章 多工化驗市場評估:各用途

  • 概要
  • 研究開發
  • 診斷
    • 感染疾病
    • 腫瘤學
    • 循環系統疾病
    • 自體免疫疾病
    • 其他的疾病

第9章 多工化驗市場評估:各終端用戶

  • 概要
  • 製藥·生物科技企業
  • 診斷研究所
  • 醫院
  • 其他的終端用戶

第10章 多工化驗市場評估:各地區

  • 概要
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 南美
    • 巴西
    • 墨西哥
    • 其他南美國家
  • 中東·非洲

第11章 競爭分析

  • 概要
  • 主要成長策略
  • 競爭基準
  • 競爭儀表板
    • 產業領導者
    • 差異化要素
    • 領先企業
    • 新興企業

第12章 企業簡介(企業概要,財務概述,產品系列,策略性展開)

  • Seegene, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • QIAGEN N.V.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • DiaSorin S.p.A.
  • PerkinElmer, Inc.
  • Agilent Technologies, Inc.
  • Abbott Laboratories
  • Siemens Healthineers AG
  • Merck KGaA
  • Quanterix Corporation

(附註:SWOT分析描述了前五名公司)

第13章 附錄

Multiplex Assays Market by Type (Protein [Bead, Planar], Nucleic Acid, Cell) Technology (Flow Cytometry, PCR, Immunoassay) Application (R&D, Diagnosis (Oncology, Cardiovascular, Infectious, Autoimmune Diseases) Product, End User-Global Forecast to 2030

The global multiplex assays market is expected to reach $6.24 billion by 2030 at a CAGR of 9.0% from 2023 to 2030.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of this market is attributed to several factors, the advantages of multiplex assays over singleplex assays, the use of multiplexing in companion diagnostics, the increasing prevalence of chronic and infectious diseases, and rising awareness about the importance of early disease diagnosis. However, the high costs of multiplex assay equipment restrain the growth of this market.

The growing need for high-throughput and automated laboratory systems and the increasing focus on personalized medicine is expected to generate growth opportunities for the players operating in this market. However, the shortage of skilled professionals and the risk of cross-reactivity are major challenges to market growth.

Among all the types studied in this report, in 2023 protein multiplex assays segment is expected to account for the largest share of the multiplex assays market. Protein multiplex assays are further segmented into bead-based assays and planar assays. In 2023, the bead-based assays segment is expected to account for the largest share of the protein multiplex assays market. Multiplex bead-based assays have become essential tools for diagnosing various diseases. These assays are used for testing allergies, cancer markers, cytokines, cardiac markers, autoimmune diseases, and endocrine diseases. Bead-based assays offer a dynamic range of analytes as they are measured using flow cytometry. They are suitable for high-throughput analysis and are much more rapid, making them the preferred alternative to planar assays.

Among all the products studied in this report, in 2023, the consumables segment is expected to account for the largest share of the multiplex assays market. The large market share of this segment is attributed to the repetitive use of kits, the growing portfolio of disease-specific kits for early diagnosis of diseases, and the increasing product approvals. The continuous advancements in reagents and kits, the development of user-friendly diagnostic kits, and the adoption of multiplex assay kits in clinical and research laboratories positively impact the demand for consumables used in multiplex assays.

Among all the technologies studied in this report, the flow cytometry segment is projected to register the highest CAGR during the forecast period. Flow cytometry is considered an important tool in clinical diagnosis and research & development. It provides a multiparametric analysis of many single cells, which can be used in multiple research areas. Additionally, market players are launching advanced flow cytometers to support growing market needs. For instance, in June 2023, Becton, Dickinson and Company (U.S.) launched a BD FACSDuet to automate sample preparation during clinical flow cytometry diagnostics.

Among all the applications studied in this report, in 2023, the research & development segment is expected to account for the largest share of the multiplex assays market. The large market share of this segment is attributed to increasing applications of multiplex assays in drug discovery, biomarker profiling, and understanding disease mechanisms. The demand for multiplex assays in research & development is increasing rapidly and is also contributing to the largest share of the segment.

Among all the end users studied in this report, the research & development segment is expected to grow at the highest CAGR during the forecast period. The highest CAGR of this segment is attributed to factors such as the increasing R&D investments by pharmaceutical & biotechnology companies, the widespread utilization of multiplex assays in drug discovery & development, and a growing emphasis on personalized medicine research. The rising spending on R&D by pharmaceutical companies is also contributing to the largest share of this segment.

An in-depth analysis of the geographical scenario of the global multiplex assays market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the multiplex assays market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America's large share is attributed to the region's high R&D spending by the pharmaceutical & biotechnology companies for the development of drugs and biomarker identification, increasing prevalence of chronic diseases, rising healthcare expenditure, presence of leading market players in the region, and favorable government initiatives for research & development. According to the U.S. Congressional Budget Office, U.S. pharmaceutical R&D expenditure increased from 91.1 billion in 2020 to 102.3 billion in 2021.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the years (2020-2023). The key players operating in the global multiplex assays market are Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Seegene, Inc. (South Korea), Qiagen N.V. (Netherlands), PerkinElmer, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Illumina, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Quanterix Corporation (U.S.), DiaSorin S.p.A. (Italy), and Merck KGaA (Germany).

Scope of the Report:

Multiplex Assays Market Assessment, by Type

  • Protein Multiplex Assays
  • Bead-based Assays
  • Planar Assay
  • Nucleic Acid Multiplex Assays
  • Cell-based Multiplex Assays

Multiplex Assays Market Assessment, by Product

  • Consumables
  • Instruments
  • Software & Services

Multiplex Assays Market Assessment, by Technology

  • Flow Cytometry
  • Multiplex Immunoassay
  • Multiplex Real-Time PCR
  • Sequencing
  • Other Technologies

Note: Other technologies consist of microarray and immunohistochemistry

Multiplex Assays Market Assessment, by Application

  • Research & Development
  • Clinical Diagnosis
  • Infectious Diseases
  • Oncology
  • Cardiovascular Diseases
  • Autoimmune Diseases
  • Other Diseases

Note: Other diseases include neurological diseases, thrombosis, and drug abuse testing.

Multiplex Assays Market Assessment, by End User

  • Pharmaceutical & Biotechnology Companies
  • Diagnostic Laboratories
  • Hospitals
  • Other End Users

Note: Other end users consist of academic institutes & research centers, forensic labs, agriculture companies, and food & beverage companies

Multiplex Assays Market Assessment, by Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe (Roe)
  • Asia-Pacific (APAC)
  • China
  • Japan
  • India
  • Rest of Asia-Pacific (RoAPAC)
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Ecosystem
  • 1.3. Currency And Limitations
  • 1.4. Key stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Process of Data Collection and Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
  • 2.3. Market Sizing and Forecasting
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
  • 2.4. Assumptions for the study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Factors Affecting Market Growth
    • 4.2.1. Market Dynamics
      • 4.2.1.1. Advantages of Multiplex Assays over Singleplex Assays Leading to Their Increased Adoption
      • 4.2.1.2. Growing Use of Multiplexing in Companion Diagnostics Driving the Demand for Multiplex Assays
      • 4.2.1.3. High Costs of Multiplex Assay Equipment Hampering Adoption Among End Users
      • 4.2.1.4. Increasing Focus on Personalized Medicine Boosting the Utilization of Multiplex Assays
      • 4.2.1.5. Shortage of Skilled Professionals and the Risk of Cross-reactivity Limiting the Adoption of Multiplex Assays
    • 4.2.2. Factor Analysis
  • 4.3. Technology Trends
    • 4.3.1. Technological Advancements in Multiplex PCR Technology
    • 4.3.2. Integration of Artificial Intelligence and Machine Learning into Multiplex Assay Systems
    • 4.3.3. Development of Smartphone-based Diagnostic Testing Platforms
  • 4.4. Regulatory Analysis
    • 4.4.1. North America
      • 4.4.1.1. U.S.
      • 4.4.1.2. Canada
    • 4.4.2. Europe
    • 4.4.3. Asia-Pacific
      • 4.4.3.1. China
      • 4.4.3.2. India
      • 4.4.3.3. Japan
      • 4.4.3.4. South Korea
    • 4.4.4. Latin America
    • 4.4.5. Middle East & Africa
  • 4.5. Pricing Analysis
  • 4.6. Porter's Five Forces Analysis
    • 4.6.1. Bargaining Power of Suppliers
    • 4.6.2. Bargaining Power of Buyers
    • 4.6.3. Threat of Substitutes
    • 4.6.4. Threat of New Entrants
    • 4.6.5. Degree of Competition

5. Multiplex Assays Market Assessment-by Type

  • 5.1. Overview
  • 5.2. Protein Multiplex Assays
    • 5.2.1. Bead-based Assays
    • 5.2.2. Planar Assays
  • 5.3. Nucleic Acid Multiplex Assays
  • 5.4. Cell-based Multiplex Assays

6. Multiplex Assays Market Assessment- by Product

  • 6.1. Overview
  • 6.2. Consumables
  • 6.3. Instruments
  • 6.4. Software & Services

7. Multiplex Assays Market Assessment- by Technology

  • 7.1. Overview
  • 7.2. Flow Cytometry
  • 7.3. Multiplex Immunoassay
  • 7.4. Multiplex Real-time PCR
  • 7.5. Sequencing
  • 7.6. Other Technologies

8. Multiplex Assays Market Assessment- by Application

  • 8.1. Overview
  • 8.2. Research & Development
  • 8.3. Clinical Diagnosis
    • 8.3.1. Infectious Diseases
    • 8.3.2. Oncology
    • 8.3.3. Cardiovascular Diseases
    • 8.3.4. Autoimmune Diseases
    • 8.3.5. Other Diseases

9. Multiplex Assays Market Assessment- by End User

  • 9.1. Overview
  • 9.2. Pharmaceutical & Biotechnology Companies
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals
  • 9.5. Other End Users

10. Multiplex Assays Market Assessment-by Geography

  • 10.1. Overview
  • 10.2. North America
    • 10.2.1. U.S.
    • 10.2.2. Canada
  • 10.3. Europe
    • 10.3.1. Germany
    • 10.3.2. France
    • 10.3.3. U.K.
    • 10.3.4. Italy
    • 10.3.5. Spain
    • 10.3.6. Rest of Europe
  • 10.4. Asia-Pacific
    • 10.4.1. China
    • 10.4.2. Japan
    • 10.4.3. India
    • 10.4.4. Rest of Asia-Pacific
  • 10.5. Latin America
    • 10.5.1. Brazil
    • 10.5.2. Mexico
    • 10.5.3. Rest of Latin America
  • 10.6. Middle East & Africa

11. Competition Analysis

  • 11.1. Overview
  • 11.2. Key Growth Strategies
  • 11.3. Competitive Benchmarking
  • 11.4. Competitive Dashboard
    • 11.4.1. Industry Leaders
    • 11.4.2. Differentiators
    • 11.4.3. Vanguards
    • 11.4.4. Emerging Companies

12. Company Profiles (Company Overview, Financial Snapshot, Product Portfolio, and Strategic Developments)

  • 12.1. Seegene, Inc.
  • 12.2. F. Hoffmann-La Roche Ltd.
  • 12.3. Thermo Fisher Scientific, Inc.
  • 12.4. Illumina, Inc.
  • 12.5. QIAGEN N.V.
  • 12.6. Becton, Dickinson and Company
  • 12.7. Bio-Rad Laboratories, Inc.
  • 12.8. DiaSorin S.p.A.
  • 12.9. PerkinElmer, Inc.
  • 12.10. Agilent Technologies, Inc.
  • 12.11. Abbott Laboratories
  • 12.12. Siemens Healthineers AG
  • 12.13. Merck KGaA
  • 12.14. Quanterix Corporation

(Note: SWOT analysis is provided for the top 5 companies)

13. Appendix

  • 13.1. Available Customization
  • 13.2. Related Reports

List of Tables

  • Table 1 Estimated Number of New Cancer Cases, by Type (2020 Vs. 2030)
  • Table 2 Some of The Emergency Use Authorizations (EUA) Granted for Multiplex Assays During the Covid-19 Pandemic
  • Table 3 Medical Devices Regulatory Authorities in the Rest of APAC Countries
  • Table 4 IVD Regulatory Systems, by Country
  • Table 5 Average Selling Price of Multiplex Assays Products (Price/ USD)
  • Table 6 Thermo Fisher Scientific, Inc. (U.S.): Multiplex Assays Prices
  • Table 7 R&D Systems (U.S.): Multiplex Assays Prices
  • Table 8 Quanterix Corporation (U.S.): Multiplex Assays Prices
  • Table 9 Global Multiplex Assays Market, by Type, 2021- 2030 (USD Million)
  • Table 10 Global Protein Multiplex Assays Market, by Type, 2021- 2030 (USD Million)
  • Table 11 Global Protein Multiplex Assays Market, by Country/Region, 2021- 2030 (USD Million)
  • Table 12 Global Multiplex Assays Market for Bead-based Assays, by Country/Region, 2021- 2030 (USD Million)
  • Table 13 Global Multiplex Assays Market for Planar Assays, by Country/Region, 2021-2030 (USD Million)
  • Table 14 Global Multiplex Assays Market for Nucleic Acid Multiplex Assays, by Country/Region, 2021-2030 (USD Million)
  • Table 15 Global Multiplex Assays Market for Cell-Based Multiplex Assays, by Country/Region, 2021-2030 (USD Million)
  • Table 16 Global Multiplex Assays Market, by Product, 2021- 2030 (USD Million)
  • Table 17 Key Companies Offering Consumables for Multiplex Assays
  • Table 18 Global Multiplex Assays Market for Consumables, by Country/Region, 2021-2030 (USD Million)
  • Table 19 Global Multiplex Assays Market for Instruments, by Country/Region, 2021-2030 (USD Million)
  • Table 20 Key Companies Offering Software
  • Table 21 Global Multiplex Assays Market for Software & Services, by Country/Region, 2021-2030 (USD Million)
  • Table 22 Global Multiplex Assays Market, by Technology, 2021- 2030 (USD Million)
  • Table 23 Global Multiplex Assays Market for Flow Cytometry, by Country/Region, 2021-2030 (USD Million)
  • Table 24 Global Multiplex Assays Market for Multiplex Immunoassay, by Country/Region, 2021-2030 (USD Million)
  • Table 25 Global Multiplex Assays Market for Multiplex Real-Time PCR, by Country/Region, 2021-2030 (USD Million)
  • Table 26 Global Multiplex Assays Market for Sequencing, by Country/Region, 2021-2030 (USD Million)
  • Table 27 Global Multiplex Assays Market for Other Technologies, by Country/Region, 2021-2030 (USD Million)
  • Table 28 Global Multiplex Assays Market, by Application, 2021- 2030 (USD Million)
  • Table 29 Global Multiplex Assays Market for Research & Development, by Country/Region, 2021-2030 (USD Million)
  • Table 30 Global Multiplex Assays Market for Clinical Diagnosis, by Type, 2021-2030 (USD Million)
  • Table 31 Global Multiplex Assays Market for Clinical Diagnosis, by Country/Region, 2021-2030 (USD Million)
  • Table 32 COVID-19 Testing Kits
  • Table 33 Global Multiplex Assays Market for Infectious Diseases, by Country/Region, 2021-2030 (USD Million)
  • Table 34 Global Multiplex Assays Market for Oncology, by Country/Region, 2021-2030 (USD Million)
  • Table 35 Global Multiplex Assays Market for Cardiovascular Diseases, by Country/Region, 2021-2030 (USD Million)
  • Table 36 Global Multiplex Assays Market, For Autoimmune Diseases, by Country/Region, 2021-2030 (USD Million)
  • Table 37 Global Multiplex Assays Market for Other Diseases, by Country/Region, 2021-2030 (USD Million)
  • Table 38 Global Multiplex Assays Market, by End User, 2021- 2030 (USD Million)
  • Table 39 Global Multiplex Assays Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2021-2030 (USD Million)
  • Table 40 Global Multiplex Assays Market for Diagnostic Laboratories, by Country/Region, 2021-2030 (USD Million)
  • Table 41 Global Multiplex Assays Market for Hospitals, by Country/Region, 2021-2030 (USD Million)
  • Table 42 Global Multiplex Assays Market for Other End Users, by Country/Region, 2021-2030 (USD Million)
  • Table 43 Global Multiplex Assays Market, by Country/Region, 2021- 2030 (USD Million)
  • Table 44 North America: Multiplex Assays Market, by Country, 2021-2030 (USD Million)
  • Table 45 North America: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 46 North America: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 47 North America: Multiplex Assays Market, by Product, 2021-2030 (USD Million)
  • Table 48 North America: Multiplex Assays Market, by Technology, 2021-2030 (USD Million)
  • Table 49 North America: Multiplex Assays Market, by Application, 2021-2030 (USD Million)
  • Table 50 North America: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021-2030 (USD Million)
  • Table 51 North America: Multiplex Assays Market, by End User, 2021-2030 (USD Million)
  • Table 52 U.S.: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 53 U.S.: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 54 U.S.: Multiplex Assays Market, by Product, 2021-2030 (USD Million)
  • Table 55 U.S.: Multiplex Assays Market, by Technology, 2021-2030 (USD Million)
  • Table 56 U.S.: Multiplex Assays Market, by Application, 2021-2030 (USD Million)
  • Table 57 U.S.: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021-2030 (USD Million)
  • Table 58 U.S.: Multiplex Assays Market, by End User, 2021-2030 (USD Million)
  • Table 59 Canada: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 60 Canada: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 61 Canada: Multiplex Assays Market, by Product, 2021-2030 (USD Million)
  • Table 62 Canada: Multiplex Assays Market, by Technology, 2021-2030 (USD Million)
  • Table 63 Canada: Multiplex Assays Market, by Application, 2021-2030 (USD Million)
  • Table 64 Canada: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021-2030 (USD Million)
  • Table 65 Canada: Multiplex Assays Market, by End User, 2021-2030 (USD Million)
  • Table 66 Europe: Multiplex Assays Market, by Country/Region, 2021-2030 (USD Million)
  • Table 67 Europe: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 68 Europe: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 69 Europe: Multiplex Assays Market, by Product, 2021-2030 (USD Million)
  • Table 70 Europe: Multiplex Assays Market, by Technology, 2021-2030 (USD Million)
  • Table 71 Europe: Multiplex Assays Market, by Application, 2021-2030 (USD Million)
  • Table 72 Europe: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021-2030 (USD Million)
  • Table 73 Europe: Multiplex Assays Market, by End User, 2021-2030 (USD Million)
  • Table 74 Germany: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 75 Germany: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 76 Germany: Multiplex Assays Market, by Product, 2021-2030 (USD Million)
  • Table 77 Germany: Multiplex Assays Market, by Technology, 2021-2030 (USD Million)
  • Table 78 Germany: Multiplex Assays Market, by Application, 2021-2030 (USD Million)
  • Table 79 Germany: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021-2030 (USD Million)
  • Table 80 Germany: Multiplex Assays Market, by End User, 2021-2030 (USD Million)
  • Table 81 France: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 82 France: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 83 France: Multiplex Assays Market, by Product, 2021-2030 (USD Million)
  • Table 84 France: Multiplex Assays Market, by Technology, 2021-2030 (USD Million)
  • Table 85 France: Multiplex Assays Market, by Application, 2021-2030 (USD Million)
  • Table 86 France: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021-2030 (USD Million)
  • Table 87 France: Multiplex Assays Market, by End User, 2021-2030 (USD Million)
  • Table 88 U.K.: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 89 U.K.: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 90 U.K.: Multiplex Assays Market, by Product, 2021-2030 (USD Million)
  • Table 91 U.K.: Multiplex Assays Market, by Technology, 2021-2030 (USD Million)
  • Table 92 U.K.: Multiplex Assays Market, by Application, 2021-2030 (USD Million)
  • Table 93 U.K.: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021-2030 (USD Million)
  • Table 94 U.K.: Multiplex Assays Market, by End User, 2021-2030 (USD Million)
  • Table 95 Italy: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 96 Italy: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 97 Italy: Multiplex Assays Market, by Product, 2021-2030 (USD Million)
  • Table 98 Italy: Multiplex Assays Market, by Technology, 2021-2030 (USD Million)
  • Table 99 Italy: Multiplex Assays Market, by Application, 2021-2030 (USD Million)
  • Table 100 Italy: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021-2030 (USD Million)
  • Table 101 Italy: Multiplex Assays Market, by End User, 2021-2030 (USD Million)
  • Table 102 Spain: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 103 Spain: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 104 Spain: Multiplex Assays Market, by Product, 2021-2030 (USD Million)
  • Table 105 Spain: Multiplex Assays Market, by Technology, 2021-2030 (USD Million)
  • Table 106 Spain: Multiplex Assays Market, by Application, 2021-2030 (USD Million)
  • Table 107 Spain: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021-2030 (USD Million)
  • Table 108 Spain: Multiplex Assays Market, by End User, 2021-2030 (USD Million)
  • Table 109 COVID-19 Cases in European Countries
  • Table 110 Rest of Europe: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 111 Rest of Europe: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 112 Rest of Europe: Multiplex Assays Market, by Product, 2021-2030 (USD Million)
  • Table 113 Rest of Europe: Multiplex Assays Market, by Technology, 2021-2030 (USD Million)
  • Table 114 Rest of Europe: Multiplex Assays Market, by Application, 2021-2030 (USD Million)
  • Table 115 Rest of Europe: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021-2030 (USD Million)
  • Table 116 Rest of Europe: Multiplex Assays Market, by End User, 2021-2030 (USD Million)
  • Table 117 Asia-Pacific: Multiplex Assays Market, by Country/Region, 2021-2030 (USD Million)
  • Table 118 Asia-Pacific: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 119 Asia-Pacific: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 120 Asia-Pacific: Multiplex Assays Market, by Product, 2021-2030 (USD Million)
  • Table 121 Asia-Pacific: Multiplex Assays Market, by Technology, 2021-2030 (USD Million)
  • Table 122 Asia-Pacific: Multiplex Assays Market, by Application, 2021-2030 (USD Million)
  • Table 123 Asia-Pacific: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021-2030 (USD Million)
  • Table 124 Asia-Pacific: Multiplex Assays Market, by End User, 2021-2030 (USD Million)
  • Table 125 China: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 126 China: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 127 China: Multiplex Assays Market, by Product, 2021-2030 (USD Million)
  • Table 128 China: Multiplex Assays Market, by Technology, 2021-2030 (USD Million)
  • Table 129 China: Multiplex Assays Market, by Application, 2021-2030 (USD Million)
  • Table 130 China: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021-2030 (USD Million)
  • Table 131 China: Multiplex Assays Market, by End User, 2021-2030 (USD Million)
  • Table 132 Japan: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 133 Japan: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 134 Japan: Multiplex Assays Market, by Product, 2021-2030 (USD Million)
  • Table 135 Japan: Multiplex Assays Market, by Technology, 2021-2030 (USD Million)
  • Table 136 Japan: Multiplex Assays Market, by Application, 2021-2030 (USD Million)
  • Table 137 Japan: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021-2030 (USD Million)
  • Table 138 Japan: Multiplex Assays Market, by End User, 2021-2030 (USD Million)
  • Table 139 India: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 140 India: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 141 India: Multiplex Assays Market, by Product, 2021-2030 (USD Million)
  • Table 142 India: Multiplex Assays Market, by Technology, 2021-2030 (USD Million)
  • Table 143 India: Multiplex Assays Market, by Application, 2021-2030 (USD Million)
  • Table 144 India: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021-2030 (USD Million)
  • Table 145 India: Multiplex Assays Market, by End User, 2021-2030 (USD Million)
  • Table 146 Rest of Asia-Pacific: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 147 Rest of Asia-Pacific: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 148 Rest of Asia-Pacific: Multiplex Assays Market, by Product, 2021- 2030 (USD Million)
  • Table 149 Rest of Asia-Pacific: Multiplex Assays Market, by Technology, 2021-2030 (USD Million)
  • Table 150 Rest of Asia-Pacific: Multiplex Assays Market, by Application, 2021-2030 (USD Million)
  • Table 151 Rest of Asia-Pacific: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021-2030 (USD Million)
  • Table 152 Rest of Asia-Pacific: Multiplex Assays Market, by End User, 2021-2030 (USD Million)
  • Table 153 Latin America: Multiplex Assays Market, by Country/Region, 2021-2030 (USD Million)
  • Table 154 Latin America: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 155 Latin America: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 156 Latin America: Multiplex Assays Market, by Product, 2021-2030 (USD Million)
  • Table 157 Latin America: Multiplex Assays Market, by Technology, 2021-2030 (USD Million)
  • Table 158 Latin America: Multiplex Assays Market, by Application, 2021-2030 (USD Million)
  • Table 159 Latin America: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021-2030 (USD Million)
  • Table 160 Latin America: Multiplex Assays Market, by End User, 2021-2030 (USD Million)
  • Table 161 Brazil: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 162 Brazil: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 163 Brazil: Multiplex Assays Market, by Product, 2021-2030 (USD Million)
  • Table 164 Brazil: Multiplex Assays Market, by Technology, 2021-2030 (USD Million)
  • Table 165 Brazil: Multiplex Assays Market, by Application, 2021-2030 (USD Million)
  • Table 166 Brazil: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021-2030 (USD Million)
  • Table 167 Brazil: Multiplex Assays Market, by End User, 2021-2030 (USD Million)
  • Table 168 Mexico: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 169 Mexico: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 170 Mexico: Multiplex Assays Market, by Product, 2021-2030 (USD Million)
  • Table 171 Mexico: Multiplex Assays Market, by Technology, 2021-2030 (USD Million)
  • Table 172 Mexico: Multiplex Assays Market, by Application, 2021-2030 (USD Million)
  • Table 173 Mexico: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021-203 ( USD Million)
  • Table 174 Mexico: Multiplex Assays Market, by End User, 2021-2030 (USD Million)
  • Table 175 Rest of Latin America: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 176 Rest of Latin America: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 177 Rest of Latin America: Multiplex Assays Market, by Product, 2021-2030 (USD Million)
  • Table 178 Rest of Latin America: Multiplex Assays Market, by Technology, 2021-2030 (USD Million)
  • Table 179 Rest of Latin America: Multiplex Assays Market, by Application, 2021-2030 (USD Million)
  • Table 180 Rest of Latin America: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021-2030 (USD Million)
  • Table 181 Rest of Latin America: Multiplex Assays Market, by End User, 2021-2030 (USD Million)
  • Table 182 Middle East & Africa: Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 183 Middle East & Africa: Protein Multiplex Assays Market, by Type, 2021-2030 (USD Million)
  • Table 184 Middle East & Africa: Multiplex Assays Market, by Product, 2021- 2030 (USD Million)
  • Table 185 Middle East & Africa: Multiplex Assays Market, by Technology, 2021- 2030 (USD Million)
  • Table 186 Middle East & Africa: Multiplex Assays Market, by Application, 2021- 2030 (USD Million)
  • Table 187 Middle East & Africa: Multiplex Assays Market for Clinical Diagnosis Application, by Type, 2021- 2030 (USD Million)
  • Table 188 Middle East & Africa: Multiplex Assays Market, by End User, 2021- 2030 (USD Million)
  • Table 189 Recent Developments, by Company, 2020-2023